Nanomedicine for biofilm associated infections: opportunities, challenges, and clinical translation

Husni Farah Munthar Kadhim-Abosaoda Hayjaa Mohaisen-Mousa S. Jyothi Priya Priyadarshini-Nayak Bethanney Janney.J Gurjant Singh Ashish Singh-Chauhan

Aug 2026 · Microfluidics and Nanofluidics · Vol 30 · 0 citations · 111 references

TL;DR

Comparative studies suggest that combination approaches, including enzyme functionalized or stimuli responsive nanoparticles paired with antibiotics, may outperform single modality treatments by simultaneously disrupting the biofilm matrix and delivering active agents.

DOI Semantic Scholar

View source

Similar papers

Review Open access 2026

Nanoparticle-antibiotic synergy against bacterial biofilms: mechanisms, therapeutic potential, and future directions

Bacterial biofilms pose significant challenges in clinical and industrial settings because of their resistance up to 1000-fold higher than that of planktonic bacteria. This resistance arises from extracellular polymeric matrix, reduced metabolic activity, and horizontal gene transfer. The growing burden of biofilm-asso...

I. C. Oladipo, K. Oloyede, O. B. Ogunleke et al. · Nano Plus Science and Techno... · 0 citations

Review Open access Sep 2026

Nanodrug Delivery Systems for Lower Respiratory Infections: Pulmonary Targeting, Anti-Infective Applications, and Translational Challenges

This review systematically summarize recent advances in NDDS for LRIs, with emphasis on the design principles and functional characteristics of lipid-based, polymeric, inorganic, and hybrid nanocarriers, and connects these platforms with disease-specific therapeutic challenges in bacterial pneumonia, tuberculosis, vira...

Wen-bin Zhu, Ting-Ji Liu, Guang-Liang Cheng et al. · International Journal of Nan... · 0 citations

Sep 2026

Nano-Carriers in Biofilm-Associated Infections: Clinical Challenges, Regulatory Hurdles, and Translational Perspectives.

Biofilms are structured communities of microorganisms encapsulated by an Extracellular Polymeric Substance (EPS) matrix, which plays a crucial role in recurrent and chronic infections caused by implanted medical devices. The natural resistance of biofilms to antimicrobials and the difficulty in diagnosing them pose a c...

Avinash Verma, Shaweta Sharma · Recent Advances in Drug Deli... · 0 citations

Review Open access Aug 2026

Lipid nanoparticle-based drug delivery for invasive fungal infections: engineering strategies, therapeutic advances, clinical translation, and future perspectives

Invasive fungal infections (IFIs) remain a major cause of morbidity and mortality among immunocompromised patients despite the availability of multiple antifungal agents. Their clinical management is frequently limited by poor aqueous solubility, inadequate tissue penetration, systemic toxicity, unfavorable pharmacokin...

Abdul Shadab · Health Nanotechnology · 0 citations

Review Open access Sep 2026

Nanomedicine against antimicrobial resistance: mechanistic insights and next-generation therapeutic potential

This review comprehensively examines resistance mechanisms across major microbial pathogens and discusses the evolution of nanomedicine as an advanced platform for combating AMR, highlighting the synergistic interactions between nanomaterials and conventional antimicrobial agents that enhance therapeutic efficacy and r...

Vishal L. Handa, Benedict B. Vyas, Abhishek Padhi et al. · Frontiers in Chemistry · 0 citations

Conference Open access Sep 2026

A Comprehensive Review of Antimicrobial Nanoformulations: Engineered to Combat Biofilm-Associated Infections

This review establishes a consolidated evidence base for the design of next-generation antimicrobial nanoformulations, highlights their potential to address biofilm-associated infections, and identifies key knowledge gaps and translation barriers that must be addressed to realize their therapeutic promise.

Praveen Kumar Annagowni, Renuka Gudepu, S. Dahariya et al. · Micro · 0 citations